Stock Expert AI
Cigna Corporation
CI - NYSE - $273.87 ▼ -%1.63
-
Earnings Thu 29 Oct

Cigna opens the
books on Thursday evening.

12 analysts' median target is $340[FMP target], stock is $274, +24.1% upside potential. After Q1 +2.4% EPS beat[FMP earnings], the stock moved -3.0%.

summary below
Quick Take - in 40 seconds
A-
BUY Council 2/6 - Moonshot 30

A- = MoonshotScore 30[multi-pillar formula] + Council 2/6[6-lens rule]. Form 4: 0 transactions[FMP Form 4].

Q1 consensus: revenue $72.7B[FMP est], EPS $7.50[FMP est]. 6 consecutive quarters of beat[FMP earnings].

$7.50 EPS Estimate Last year $7.79 - -4% YoY YoY
6 Beat Streak Expectations beaten consecutively for the last 6 quarters

Q1 EPS +2.4% beat[FMP] but the stock -3.0% D+1[FMP D+1]. Ann Dennison promised $297.0M CapEx + a sequential decline in Q1 during the Q1 earnings call[Ann Dennison capex transcript].

Watchlist

4 metrics stand out this quarter.

20% Investor Focus

Evernorth Specialty Growth

evernorth_specialty_growth

Evernorth's Specialty and Care Services business delivered strong adjusted earnings growth of 20% in Q1 2026, driven by attractive volume growth and demand for specialty drugs.

"Specialty and Care Services showed strong growth with pretax adjusted earnings up 20% to $1.1 billion. This performance reflects continued momentum in our fastest-growing business, including strong demand for specialty drugs and increased biosimilar and specialty generic adoption, which are key levers for delivering affordability and value to patients and clients."

- Ann Dennison, CFO - Q1 FY26 Earnings Call - April 30, 2026
2026 Expectation / Guide

Fy26 Eps Guidance Raise

fy26_eps_guidance_raise

Cigna Group has raised its full year 2026 adjusted EPS outlook to at least $30.35, reflecting strong first-quarter performance and disciplined execution.

"With our performance, we are raising our full year 2026 adjusted EPS outlook to at least $30.35, reflecting our disciplined approach and steady execution in an operating environment that continues to be shaped by many forces."

- David Cordani, CEO - Q1 FY26 Earnings Call - April 30, 2026
20% Investor Focus

Ai Driven Personalization Affordability

ai_driven_personalization_affordability

Cigna is leveraging AI and advanced analytics to enhance customer experience, drive affordability, and personalize health services, leading to a 20% drop in inbound calls for digitally eligible customers.

"The combination of our AI tools and contact centers and improved customer digital experiences led to a 20% drop in total inbound calls for digitally eligible customer in our Cigna Healthcare U.S. employer business and a 25% reduction for pharmacy benefit services members when compared to just 2 years ago."

- Brian Evanko, President and COO - Q1 FY26 Earnings Call - April 30, 2026
2026 Investor Focus

Individual Exchange Exit

individual_exchange_exit

Cigna plans to exit its individual exchange business at the end of 2026 to sharpen focus on core platforms where it can deliver differentiated value.

"First, we are planning to exit our individual exchange business at the end of this year. We did not make this decision lightly and appreciate the importance of ensuring patients have continuity through the transition."

- Brian Evanko, President and COO - Q1 FY26 Earnings Call - April 30, 2026

Stock Expert AI - Methodology

Do our scoring pillars, 7 perspectives, and Munger lens point in the same direction?

Council Score 2 / 6 Bullish

6 investor frameworks. 2 bullish (Ray Dalio, Buffett), 1 bearish (Ken Griffin), 3 neutral (Jim Simons, Klarman, Munger).

How is it calculated? ->
Ray Dalio macro - target upside +24.1%
Ken Griffin flow - 50d MA below
Jim Simons quant - RSI 43
Klarman value - target upside +24.1%
Buffett quality - ROE score 4/5
Munger valuation - target upside +24.1%
Munger's Mindset character & balance sheet lens
Fairly Valued

Quality business, trading at fair value.

How is it calculated? ->
Financial HealthStrong
Margin of SafetyModerate
Interest CoverageAdequate
ROIC vs WACCHealthy
Technical Levels - Pre-earnings positioning

What levels is the stock being tested at?

RSI(14)
42.6 RSI 42.6 weak momentum, 50d below
MACD
-4.10 price below 50d - resistance dominant
50d MA
$286 stock 4.1% below - short-term resistance
200d MA
$279 stock 1.9% below - long-term pressure
Volume (10d)
-41% decrease - low participation
Resistance
$340
Analyst median target - upgrade trigger if broken
Current
$274
Pre-earnings position
Support
$237
Invalidation - close below this is a technical breakdown
Pattern
Range
$237-$340 band - earnings breakout/breakdown trigger

Past Performance

Cigna's last 8 quarters: 6 consecutive beats.

BEAT
Q3 FY25
$7.83 vs $7.64 est - -1.1%
BEAT
Q4 FY25
$8.08 vs $7.88 est - +2.6%
BEAT
Q1 FY26
$7.79 vs $7.60 est - -2.6%
BEAT
Q2 FY26
$7.78 vs $7.60 est - -3.0%

Q1 (April 30, 2026): EPS $7.78 vs $7.60 est[FMP], +2.4% beat. D+1 movement: -3.0%[FMP D+1]. Decline despite beat - market reacted to guidance, not numbers.

Three scenarios: what could happen?

EPS < $7.27 (no guidance)

Q1: EPS $7.78 vs $7.60 beat[FMP], stock -3.0% D+1[FMP].

Backlog concentration

No RPO/backlog concentration disclosed in Q1 earnings call.

CapEx shock

Q1 CapEx $297.0M[FMP cashflow]. Q1 op margin 3.7%[FMP op margin] - this level in Q1 is sensitive to CapEx revision risk.

Framework - Position discipline

After the data arrives: 3 scenarios, 3 windows

Not advice - a structural framework for earnings night. Decision discipline is yours.

Scenario A - Beat
Q1 EPS > $7.50 + CapEx discipline
Threshold: EPS > $7.50[FMP est].
Target: Break above median target $340[FMP target]; high target $400[FMP] upper bound.
Scenario B - In-Line
EPS approx $7.50 + CapEx < $297.0M
Threshold: EPS approx $7.50[FMP est], Q1 CapEx < $297.0M[FMP].
Target: Consolidation in the band between current $274[FMP] and median $340[FMP].
Scenario C - Miss
EPS < $7.27 or CapEx >= $297.0M
Threshold: EPS < $7.27[FMP estx0.97].
Target: Current $274 below SMA200 $279[FMP], if rejection continues, $237[derived] support activates.
Sizing
Earnings volatility -> max portfolio 1-2%. Waiting for earnings is not a gamble, it's a position entrustment.
Timing
IV crush within 24 hours post-earnings. Waiting for premium decay makes options preferable to spot.
Staging
Don't go all-in at once, divide into 3: initial reaction, 24 hours later, after Friday's close.

Market Outlook

What do 12 analysts say?

Wall Street Consensus
$340
12-month median target price (+24.1% upside potential)
20
BUY
4
HOLD
0
SELL
Risk Management
$237
Invalidation level - critical support threshold
$286 - 50-day MA (below, -4.1%)
$279 - 200-day MA (below, -1.9%)
IV Crush risk (sudden drop in inflated option premiums before earnings): Option premiums are inflated before earnings.
Verdict - CI Q1 FY27
A-

You read it in 5 minutes. When the numbers come out on Thursday evening - you know what you're looking at.

Data arrives at night. The framework is ready now.

Data arrives on Thursday evening. The framework is ready on this page: Q1 EPS threshold $7.50[FMP], CapEx threshold "below $297.0M"[Ann Dennison]. Two anchors, three scenarios.

Comparison Stock Expert AI Pro $24/month ($240/year), 77% cheaper than the total of three earnings-tracking tools ($1,059/year -> $240/year).

3 subscriptions. 1 platform.

Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts

Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing

Stock Expert AI Pro: $24/month ($240/year). Council 7-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.

Educational tool, not investment advice. Past performance does not guarantee future results.

Calendar

Catalyst Calendar - 90-day forward look

Oct 29, 2026EARNINGSQ1 FY27 results (after market close) + earnings call
Oct 30, 2026PRICEFirst trading day after earnings - 200dMA test + IV crush
Dec 13, 2026FILING10-Q deadline - segment breakdown + RPO detail (SEC rule: quarter-end + 45 days)
~Jan 29, 2027EARNINGSQ2 FY27 (next quarter, date not yet scheduled in FMP)

DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.

Frequently Asked Questions

What does the CI earnings preview cover?

This Cigna Corporation (CI) earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.

What should investors watch for in CI earnings?

Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.

Where do the numbers on this page come from?

Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.

Is this a buy or sell recommendation?

No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.

More earnings, decoded